CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a new treatment for dyslipidemia and non-alcoholic fatty liver disease using peptide-nuclear hormone conjugates. By combining glucagon and thyroid hormone, the aim is to deliver targeted therapy to the liver, reducing lipid levels and reversing liver fat accumulation without adverse c…
Cardiovascular disease (CVD) is a leading cause of death worldwide.
Compelling evidence indicates that dyslipidemia represent a key risk factor for CVD.
Among approved lipid-lowering agents, statins are the most effective therapy for CVD.
However, a substantial portion of high-risk patients treated with statins fail to achieve target cholesterol levels required for preventing CVD.
Thus, sufficiently efficacious and safe alternatives are urgently required.
In addition, non-alcoholic fatty liver d…
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
